Medical
Time to end needless repeat referrals to specialists
Medical News: “It’s high time that Australia’s referral system to specialist care was brought up to date in the interests of patients and to meet management requirements for today’s ongoing chronic health conditions,” said Alison Verhoeven, Chief Executive of the Australian Healthcare and Hospitals Association (AHHA).
Ms Verhoeven was commenting on yesterday’s release by the AHHA’s Deeble Institute for Health Policy Research of an Issues Brief, Optimising health care through specialist referral reforms.
“When the Medicare referral rules were put in place in the 70s, most referrals related to acute conditions that could be managed within a 12-month period.
“Now referrals are typically for management of an ongoing chronic condition, around 50% of Australian adults live with an ongoing health condition,” Ms Verhoeven said.
“So the standard 12-month referral will expire during your ongoing course of treatment and you will be asked to go back to your GP to get another referral if you want the specialist appointment to be Medicare-rebatable.
“If a patient is seeing more than one specialist, keeping track of the validity of all referrals can be a nightmare.
“The reason often given for repeat referrals is “to keep the GP involved in your care” – but most specialists report back to the patient’s GP on the care being provided to the patient. And a GP can ask to see a patient when there is a clinical need for it.
“Using a repeat referral to trigger GP involvement is not an optimal use of the medical workforce. And, typically, the appointment with the GP for a repeat referral will not change care provided by the specialist in any significant way.
“After a patient sees their GP, and pays any gap fee applied, they go back to the specialist and, because the rules are ambiguous, many specialists will charge a higher ‘’initial consultation” fee with a higher gap payment because it is a ‘new’ referral.
“Our Medicare system is something to be proud of, but it is not a bottomless pit so why are we paying professional fees for what in many cases is a mini-lap of the health system that is of little value to the patient, and over which the patient has little control?
“A similar situation applies to specialist-to-specialist referrals, where the standard period of referral is three months. It’s easy to see how, say, a cancer patient receiving both radiation and chemotherapy treatment will have regularly-expiring specialist-to-specialist referrals.
“A curiosity of the referral system is that while referrals from GP to specialist last for a standard 12 months, indefinite referrals are permitted, with regulations only requiring practitioners to consider the general “need” for such a referral.
“In short, the rules requiring patients to obtain repeat referrals have remained unchanged since the 1970s. There are many arguments for changing these rules to having no time limits on referrals to specialists, expanding referral rights, collecting better data on referrals and referral pathways, regular reviews of the rules, and decoupling specialist billing from referral status – all as part of enabling better-coordinated continuous care.
“But above all, it is high time there was an independent, evidence-based review of the whole referral system, to properly examine its costs and benefits, and bring it up to date to better suit consumer needs,” Ms Verhoeven said.
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More